Details for Patent: 9,320,455
Which drugs does patent 9,320,455 protect, and when does it expire?
Patent 9,320,455 protects ABILIFY MYCITE KIT and is included in one NDA.
This patent has twenty-seven patent family members in seventeen countries.
Summary for Patent: 9,320,455
| Title: | Highly reliable ingestible event markers and methods for using the same |
| Abstract: | Ingestible event markers having high reliability are provided. Aspects of the ingestible event markers include a support, a control circuit, a first electrochemical material, a second electrochemical material and a membrane. In addition, the ingestible event markers may include one or more components that impart high reliability to the ingestible event marker. Further, the ingestible event markers may include an active agent. In some aspects, the active agent, such as a pharmaceutically active agent or a diagnostic agent may be associated with the membrane. |
| Inventor(s): | Hooman Hafezi, Kityee Au-Yeung, Robert Duck, Maria Casillas Holen, Timothy Robertson, Benedict James Costello |
| Assignee: | Otsuka Pharmaceutical Co Ltd |
| Application Number: | US13/756,280 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 9,320,455
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-001 | Nov 13, 2017 | DISCN | Yes | No | 9,320,455 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | DISCN | Yes | No | 9,320,455 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-003 | Nov 13, 2017 | DISCN | Yes | No | 9,320,455 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-004 | Nov 13, 2017 | DISCN | Yes | No | 9,320,455 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-005 | Nov 13, 2017 | DISCN | Yes | No | 9,320,455 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-006 | Nov 13, 2017 | DISCN | Yes | No | 9,320,455 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,320,455
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 122013009559 | ⤷ Start Trial | |||
| Brazil | PI1015298 | ⤷ Start Trial | |||
| Chile | 2011002700 | ⤷ Start Trial | |||
| China | 102458236 | ⤷ Start Trial | |||
| Costa Rica | 20110624 | ⤷ Start Trial | |||
| Eurasian Patent Organization | 201190281 | ⤷ Start Trial | |||
| Ecuador | SP11011478 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
